NRX Pharmaceuticals Inc.(NRXP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NRXP NRX Pharmaceuticals Inc.

Market Closed 03-13 16:00:00 EDT

1.86

+0.06

+3.33%

盘后1.86

+0.000.00%

19:55 EDT

High1.89	Low1.80	Vol350.28K
Open1.80	D1 Closing1.80	Amplitude4.72%
Mkt Cap59.28M	Tradable Cap42.93M	Total Shares31.87M
T/O648.35K	T/O Rate1.52%	Tradable Shares23.08M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NRXP","market":"US","secType":"STK","nameCN":"NRX Pharmaceuticals Inc.","latestPrice":1.86,"timestamp":1773432000000,"preClose":1.8,"halted":0,"volume":350282,"hourTrading":{"tag":"盘后","latestPrice":1.86,"preClose":1.86,"latestTime":"19:55 EDT","volume":4367,"amount":8090.6026,"timestamp":1773446125784,"change":0,"changeRate":0,"amplitude":0.010753},"delay":0,"changeRate":0.03333333333333336,"floatShares":23082300,"shares":31872300,"eps":-2.31,"marketStatus":"Market Closed","change":0.06,"latestTime":"03-13 16:00:00 EDT","open":1.8,"high":1.885,"low":1.8,"amount":648352.9616874,"amplitude":0.047222,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.31,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1773648000000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":1.8,"preHourTrading":{"tag":"盘前","latestPrice":1.7911,"preClose":1.8,"latestTime":"08:54 EDT","volume":3564,"amount":6454.4973768,"timestamp":1773406483163,"change":-0.0089,"changeRate":-0.004944,"amplitude":0.032722},"postHourTrading":{"tag":"盘后","latestPrice":1.86,"preClose":1.86,"latestTime":"19:55 EDT","volume":4367,"amount":8090.6026,"timestamp":1773446125784,"change":0,"changeRate":0,"amplitude":0.010753},"volumeRatio":0.6483624814803629,"impliedVol":1.0684,"impliedVolPercentile":0.2789},"requestUrl":"/m/hq/s/NRXP","defaultTab":"news","newsList":[{"id":"2619871190","title":"NRX Pharmaceuticals Inc  expected to post breakeven results a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2619871190","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619871190?lang=en_us&edition=fundamental","pubTime":"2026-03-13 21:09","pubTimestamp":1773407354,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals Inc  expected to post breakeven results a share - Earnings Preview NRX Pharmaceuticals Inc NRXP.OQ NRXP.O is expected to  show a rise in quarterly revenue when it reports  results ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nL8N40119G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NRXP"],"gpt_icon":0},{"id":"2618679625","title":"NRX Pharmaceuticals Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2618679625","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618679625?lang=en_us&edition=fundamental","pubTime":"2026-03-10 02:56","pubTimestamp":1773082560,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRXP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 09, 2026 14:56 ET (18:56 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP","BK4007"],"gpt_icon":0},{"id":"2618409696","title":"Hope Therapeutics, an NRX Subsidiary (Nasdaq:Nrxp) Announces Opening of Palm Beach, Fl Clinic Offering One Day Treatment for Depression and Ptsd","url":"https://stock-news.laohu8.com/highlight/detail?id=2618409696","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618409696?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:00","pubTimestamp":1773054004,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nTUA3FCKVK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NRXP"],"gpt_icon":0},{"id":"2618248640","title":"HOPE Therapeutics, an NRx Subsidiary (Nasdaq:NRXP) Announces opening of Palm Beach, FL Clinic offering One Day treatment for Depression and PTSD","url":"https://stock-news.laohu8.com/highlight/detail?id=2618248640","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618248640?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:00","pubTimestamp":1773054000,"startTime":"0","endTime":"0","summary":"Published results have shown 87% clinical response to non-invasive Transcranial Magnetic Stimulation with neuroplastic medications.Clinical leadership by physicians trained at Harvard, Johns Hopkins, ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/09/3251672/0/en/HOPE-Therapeutics-an-NRx-Subsidiary-Nasdaq-NRXP-Announces-opening-of-Palm-Beach-FL-Clinic-offering-One-Day-treatment-for-Depression-and-PTSD.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP","BK4539","BK4007","BK4211","LENZ","HOPE","BK4139"],"gpt_icon":0},{"id":"2616551327","title":"NRX Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2616551327","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616551327?lang=en_us&edition=fundamental","pubTime":"2026-03-04 00:50","pubTimestamp":1772556600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRXP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 03, 2026 11:50 ET (16:50 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NRXP"],"gpt_icon":0},{"id":"2616989326","title":"NRx Pharmaceuticals price target raised to $45 from $40 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2616989326","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616989326?lang=en_us&edition=fundamental","pubTime":"2026-03-03 22:07","pubTimestamp":1772546872,"startTime":"0","endTime":"0","summary":"H.C. Wainwright raised the firm’s price target on NRx Pharmaceuticals (NRXP) to $45 from $40 and keeps a Buy rating on the shares. The firm says th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nrx-pharmaceuticals-price-target-raised-to-45-from-40-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nrx-pharmaceuticals-price-target-raised-to-45-from-40-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NRXP"],"gpt_icon":0},{"id":"2616331865","title":"NRx Pharmaceuticals Names Prof. Joshua Brown Chief Medical Innovation Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2616331865","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616331865?lang=en_us&edition=fundamental","pubTime":"2026-03-02 20:01","pubTimestamp":1772452895,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals Inc. has appointed Prof. Joshua C. Brown, MD, PhD, as Chief Medical Innovation Officer. Brown is a psychiatrist, neurologist, and neuroscientist focused on Transcranial Magnetic Stimulation , and will work with NRx leadership on advancing treatment approaches for depression and PTSD, including programs that combine TMS with neuroplastic medications.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nNDLWDhR0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210149790.SGD","IE00B3QW5Z07.USD","SG9999014021.USD","SG9999014013.SGD","BK4588","NRXP","LU0314104364.USD","LU2095319765.USD","LU2210150020.SGD","SG9999014005.SGD","BK4007","SG9999014039.USD","BK4585","IE00B64PRP62.GBP","NDAQ","IE00BGHQF748.EUR","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2616339270","title":"NRX Pharmaceuticals (Nasdaq: Nrxp) Appoints Prof. Joshua Brown Md, Phd, as Chief Medical Innovation Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2616339270","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616339270?lang=en_us&edition=fundamental","pubTime":"2026-03-02 20:00","pubTimestamp":1772452801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nTUA959R1P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXP","BK4007"],"gpt_icon":0},{"id":"2612744053","title":"NRX Pharmaceuticals Price Target Maintained With a $25.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2612744053","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612744053?lang=en_us&edition=fundamental","pubTime":"2026-02-19 01:06","pubTimestamp":1771434360,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRXP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 18, 2026 12:06 ET (17:06 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP","BK4007"],"gpt_icon":0},{"id":"2612499041","title":"NRX Pharmaceuticals Files Initial Beneficial Ownership Statement for Chief Operating Officer Joseph Michael Casper","url":"https://stock-news.laohu8.com/highlight/detail?id=2612499041","media":"Reuters","labels":["executive","shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612499041?lang=en_us&edition=fundamental","pubTime":"2026-02-18 08:00","pubTimestamp":1771372847,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals Inc. has filed an initial statement of beneficial ownership with the SEC. The filing names Joseph Michael Casper, Chief Operating Officer, as the beneficial owner. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRX Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 17, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nNDL10GBJm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"NRX Pharmaceuticals Files Initial Beneficial Ownership Statement for Chief Operating Officer Joseph Michael Casper","news_tag":"executive,shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NRXP"],"gpt_icon":0},{"id":"2612746886","title":"NRX Pharmaceuticals Inc - Files Prospectus for $20 Mln Common Stock - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2612746886","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612746886?lang=en_us&edition=fundamental","pubTime":"2026-02-17 22:21","pubTimestamp":1771338118,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nFWN3ZD162:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXP","BK4007"],"gpt_icon":0},{"id":"2612452853","title":"NRX Pharmaceuticals Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2612452853","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612452853?lang=en_us&edition=fundamental","pubTime":"2026-02-17 20:54","pubTimestamp":1771332840,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRXP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 17, 2026 07:54 ET (12:54 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NRXP"],"gpt_icon":0},{"id":"2612545430","title":"BRIEF-Nrx Pharmaceuticals (NasdaqNrxp) Announces Path To New Drug Application With Real World Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2612545430","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612545430?lang=en_us&edition=fundamental","pubTime":"2026-02-17 20:28","pubTimestamp":1771331280,"startTime":"0","endTime":"0","summary":"BRIEF-Nrx Pharmaceuticals (NasdaqNrxp) Announces Path To New Drug Application With Real World Data Feb 17 (Reuters) - NRX Pharmaceuticals Inc NRXP.O:NRX PHARMACEUTICALS (NASDAQ:NRXP) ANNOUNCES PATH TO","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nTUA21MT7C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NRXP"],"gpt_icon":0},{"id":"2612451678","title":"NRX Pharmaceuticals Advances NRX-100 Toward FDA Approval for Suicidal Depression","url":"https://stock-news.laohu8.com/highlight/detail?id=2612451678","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612451678?lang=en_us&edition=fundamental","pubTime":"2026-02-17 20:03","pubTimestamp":1771329784,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals Inc. announced completion of an in-person Type C guidance meeting with the US Food and Drug Administration regarding its preservative-free intravenous ketamine product, NRX-100, for the treatment of suicidal ideation in depression, including bipolar depression. Based on FDA guidance, NRx plans to use existing clinical trial data along with Real World Evidence from over 65,000 patients to support its New Drug Application. The company will work with the FDA to finalize the statistical analysis protocol for the Real World Evidence dataset. Study results have not yet been presented.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nNDL9Y5TCN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","BK4112","BK4007","SG9999014005.SGD","LU0314104364.USD","LU2095319765.USD","LU2210149790.SGD","NRXP","BK4588","NDAQ","IE00B3QW5Z07.USD","SG9999014013.SGD","IE00BKPKM429.USD","SG9999014021.USD","BK4585","LU2210150020.SGD","IE00BGHQF748.EUR","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2612745176","title":"NRX Pharmaceuticals: Will Use Clinical Trial Data in Hand With Proposed Real World Data From Osmind to Apply for NRX-100 Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2612745176","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612745176?lang=en_us&edition=fundamental","pubTime":"2026-02-17 20:00","pubTimestamp":1771329605,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nTUA21MT7C:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NRXP"],"gpt_icon":0},{"id":"2612702451","title":"NRX Pharmaceuticals Inc - Believes Path for NRX-100 Approval Based on Existing Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2612702451","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612702451?lang=en_us&edition=fundamental","pubTime":"2026-02-17 20:00","pubTimestamp":1771329605,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nTUA21MT7C:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NRXP"],"gpt_icon":0},{"id":"2612517014","title":"NRX Pharmaceuticals Inc - FDA Advises No Additional Nonclinical Data Needed for NRX Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2612517014","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612517014?lang=en_us&edition=fundamental","pubTime":"2026-02-17 20:00","pubTimestamp":1771329605,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nTUA21MT7C:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NRXP"],"gpt_icon":0},{"id":"2612451865","title":"NRX Pharmaceuticals (Nasdaq:Nrxp) Announces Path to New Drug Application With Real World Data and Broader Proposed Indication for NRX-100 (Ketamine) Following Type C FDA Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2612451865","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612451865?lang=en_us&edition=fundamental","pubTime":"2026-02-17 20:00","pubTimestamp":1771329605,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nTUA21MT7C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXP","BK4007"],"gpt_icon":0},{"id":"2612276451","title":"NRX Pharmaceuticals Inc - Co to Seek Broader Indication for NRX-100 for Depression","url":"https://stock-news.laohu8.com/highlight/detail?id=2612276451","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612276451?lang=en_us&edition=fundamental","pubTime":"2026-02-17 20:00","pubTimestamp":1771329605,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nTUA21MT7C:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXP","BK4007"],"gpt_icon":0},{"id":"2611193421","title":"NRx Pharmaceuticals Inc. Announces Date for 2025 Annual Meeting of Stockholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2611193421","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611193421?lang=en_us&edition=fundamental","pubTime":"2026-02-14 05:34","pubTimestamp":1771018475,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals Inc. has announced that its upcoming annual meeting of stockholders will be conducted in a virtual-only format. During the meeting, shareholders will vote on several key proposals, including the election of Chaim Hurvitz and Michael Taylor as Class I members of the Board of Directors to serve until the 2028 annual meeting or until their successors are appointed and qualified. Additionally, shareholders will consider the approval of an amendment to the NRx Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan and the ratification of Weinberg & Company, P.A. as the company's independent auditors for the fiscal year ending December 31, 2025. Other business matters that may properly come before the meeting or any adjournments or postponements thereof may also be addressed.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nNDL6bGFWC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NRXP"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.salbergco.com","stockEarnings":[{"period":"1week","weight":0.0941},{"period":"1month","weight":0.022},{"period":"3month","weight":-0.1014},{"period":"6month","weight":-0.3357},{"period":"1year","weight":-0.1014},{"period":"ytd","weight":-0.3137}],"compareEarnings":[{"period":"1week","weight":-0.015},{"period":"1month","weight":-0.0429},{"period":"3month","weight":-0.0286},{"period":"6month","weight":0.0074},{"period":"1year","weight":0.2011},{"period":"ytd","weight":-0.0288}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.074525},{"month":2,"riseRate":0.2,"avgChangeRate":-0.102766},{"month":3,"riseRate":0.2,"avgChangeRate":-0.063371},{"month":4,"riseRate":0.25,"avgChangeRate":-0.225146},{"month":5,"riseRate":0.75,"avgChangeRate":0.071255},{"month":6,"riseRate":0.4,"avgChangeRate":-0.166652},{"month":7,"riseRate":0.4,"avgChangeRate":0.039708},{"month":8,"riseRate":0.2,"avgChangeRate":-0.14211},{"month":9,"riseRate":0.4,"avgChangeRate":-0.012776},{"month":10,"riseRate":0.6,"avgChangeRate":0.037482},{"month":11,"riseRate":0.4,"avgChangeRate":0.048439},{"month":12,"riseRate":0.6,"avgChangeRate":0.121824}],"exchange":"NASDAQ","name":"NRX Pharmaceuticals Inc.","nameEN":"NRX Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"NRX Pharmaceuticals Inc.(NRXP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest NRX Pharmaceuticals Inc.(NRXP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"NRX Pharmaceuticals Inc.,NRXP,NRX Pharmaceuticals Inc.股票,NRX Pharmaceuticals Inc.股票老虎,NRX Pharmaceuticals Inc.股票老虎国际,NRX Pharmaceuticals Inc.行情,NRX Pharmaceuticals Inc.股票行情,NRX Pharmaceuticals Inc.股价,NRX Pharmaceuticals Inc.股市,NRX Pharmaceuticals Inc.股票价格,NRX Pharmaceuticals Inc.股票交易,NRX Pharmaceuticals Inc.股票购买,NRX Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"NRX Pharmaceuticals Inc.(NRXP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest NRX Pharmaceuticals Inc.(NRXP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction